ERNA | Eterna Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2010 - 0.2199
52 Week Range	0.1500 - 2.6300
Beta	3.53
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	52,007
Average Volume	301,854
Shares Outstanding	62,178,900
Market Cap	12,871,032
Sector	Healthcare
Industry	Biotechnology
IPO Date	1991-08-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.06
Forward P/E Ratio	N/A
EPS	-3.26
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	ERNA

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

ERNA's peers: RCUS, CGEM, ANNX, GPCR, RLAY, REVB, ZURA, PHIO, ZVSA, RNAZ, DAWN, ABOS, XFOR, INZY, VECT, PALI, UNCY, APGN, IMMX, ICVX, APLS, ITOS, TCRX

*Chart delayed

Analyzing fundamentals for ERNA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ERNA Fundamentals page.

Watching at ERNA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ERNA Technicals page.